Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Genomics & Personalized Medicine Act
The old saying “if at first you don’t succeed, try, try again” is clearly evident with supporters of the Genomics and Personalized Medicine Act (GPMA). Rep. Anna Eshoo (D-CA) is working to introduce a fifth incarnation of the bill, details of which can be found here. She is trying to succeed where then Illinois senator Barack Obama and others have failed to get their versions of the GPMA legislation past committees. Rep. Eshoo is promising to reintroduce the bill in Congress by 2012, and President Obama would likely support a revived GPMA. A Congress eye-deep in budget wars, though, may not be as generous with tax credits and other funding as biotech advocates might want. What do you think are Rep. Eshoo’s chances of succeeding?